Centers for Disease Control & Prevention, Clinician Outreach and Community Activity (COCA) Conference Call July 27, 2010.

The National Vaccine Program was established in 1986 to achieve optimal prevention of infectious diseases through immunization and optimal prevention of adverse reactions to vaccines.

The environmental challenges of weed resistance are the same for biotech crops and conventional crops if farmers do not use herbicides as directed. Learn more about stewardship practices that help farmers better control weeds and how biotechnology is reducing the impact of pesticides on the environment.

BIO advocated for a provision in financial services reform that would ease regulatory burdens for small public biotechnology companies.

The 2009 Government-Business Forum on Small Business Capital Formation recommended a permanent exemption for small companies from Section 404(b) of Sarbanes-Oxley. Additionally, they recommended that the SEC increase the public float threshold for being a small reporting company from having a public float of less than $75 million to less than $250 million.

BIO commends the SEC on its pilot circuit breaker proposal and urges the use of biotech companies in such proposal

BIO provides comment letter to SEC generally supporting the IFRS roadmap while maintaining safeguards for emerging companies during transition.

Implementation of CAN will help NIH-funded researchers bridge the precarious gap between basic research and the eventual development of new cures and treatments for many of the diseases we face today.

The letter, signed by approximately 85 patient groups, requests appropriation for CAN in FY2011

BIO applauds NIST on implementation of TIP program and urges that personalized medicine be included as an area of "critical national need"